Following case-mix adjustment, regional variation in the choice of targeted therapy became less marked, indicating the continued influence of these factors on b/tsDMARD choice, despite accumulating evidence supporting the safety of TNF inhibitors in people with cancer or interstitial lung disease [20–23]. This evidence concerns the gene TNF and cancer.